Yaqiong Li

Yaqiong Li


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
Kenichi KakudoKenichi Kakudo
Kenichi Kakudo
ZLZhiyan Liu
Zhiyan Liu
YBYanhua Bai
Yanhua Bai
YLYaqiong Li
Yaqiong Li
NKNaomi Kitayama
Naomi Kitayama
Chan Kwon JungChan Kwon Jung
Chan Kwon Jung
Current histopathological diagnosis methods cannot distinguish the two types of thyroid carcinoma: clinically significant carcinomas with a potential risk of recurrence, metastasis, and cancer death, and clinically insignificant carcinomas with a slow growth rate. Both thyroid tumors are diagnosed as “carcinoma” in current pathology practice. The clinician usually recommends surgery to the patient and the patient often accepts it because of cancer terminology. The treatment for these clinically insignificant carcinomas does not benefit the patient and negatively impacts society. The author proposed risk stratification of thyroid tumors using the growth rate (Ki-67 labeling index), which accurately differentiates four prognostically relevant risk groups based on the Ki-67 labeling index, ≥30%, ≥10 and 5 and <10%, and ≤5%. Indolent thyroid tumors with an excellent prognosis have the following four features: young age, early-stage (T1-2 M0), curatively treated, and low proliferation index (Ki-67 labeling index of ≤5%), and are unlikely to recur, metastasize, or cause cancer death. Accurate identification of these indolent tumors helps clinicians select more conservative treatments to avoid unnecessary aggressive (total thyroidectomy followed by radio-active iodine) treatments. Clinicians can alleviate the fears of patients by confirming these four features, including the low proliferation rate, in a pathology report immediately after surgery when patients are most concerned.

13 August 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
YLYaqiong Li
Yaqiong Li
JGJichang Gong
Jichang Gong
LZLingli Zhang
Lingli Zhang
Background: PHD finger protein 19 (PHF19), also known as polycomb‐like protein 3 (PCL3), promotes the progression of multiple myeloma (MM) and drug resistance; however, its role in the management of MM remains unclear. Therefore, we aimed to elucidate the correlation between PHF19 expression and treatment response, disease progression, and survival of patients with MM.Methods: Plasma cells derived from the bone marrow of 101 patients with de novo MM were collected prior to induction therapy, as were plasma cells derived from the bone marrow of 30 healthy donors. PHF19 expression in plasma cells was analyzed using quantitative reverse transcription polymerase chain reaction. Furthermore, the response to induction therapy, progression‐free survival (PFS), and overall survival (OS) were assessed.Results: PHF19 expression tends to be upregulated more often in MM patients than in healthy donors (p < 0.001) and can accurately predict MM risk (area under curve [AUC], 0.916; 95% confidence interval [CI], 0.869–0.962). Furthermore, elevated PHF19 expression was correlated with higher International Staging System (ISS) (p = 0.036) and revised ISS stages (p = 0.035). In addition, MM patients who achieved complete response (CR) exhibited reduced PHF19 compared to those who did not (p = 0.028). Moreover, increased PHF19 expression was correlated with unfavorable PFS (p = 0.006) and OS (p = 0.027) rates. Furthermore, the results of multivariate Cox analysis also revealed that PHF19 high expression was independently associated with a reduced PFS rate (hazard ratio: 2.025, p = 0.028).Conclusion: Increased PHF19 expression is correlated with poor induction therapy response and unfavorable long‐term prognosis of MM.

11 October 2021 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
YLYaqiong Li
Yaqiong Li
LZLingli Zhang
Lingli Zhang
JGJichang Gong
Jichang Gong
Objective: We aimed to investigate the relationship among epidermal growth factor–like protein-7 (EGFL7), integrin subunit beta 3 (ITGB3), and Kruppel-like factor 2 (KLF2) expressions and their clinical implication in multiple myeloma (MM). Methods: This prospective study enrolled 72 de novo symptomatic MM patients and 30 controls, and then collected their bone marrow plasma cell samples. Subsequently, the EGFL7, ITGB3, and KLF2 expressions were carried out by reverse transcription quantitative polymerase chain reaction. Results: EGFL7, ITGB3, and KLF2 expressions were increased in MM patients compared to controls. Besides, EGFL7, ITGB3, and KLF2 inter-correlated with each other in MM patients but not in controls. In MM patients, EGFL7 and ITGB3 (but not KLF2) expressions were positively correlated with ISS stage, while ITGB3 and KLF2 (but not EGFL7) expressions were correlated with increased R-ISS stage. Interestingly, ITGB3 and KLF2 were decreased in induction-treatment complete remission (CR) MM patients compared to non-CR MM patients, while EGFL7 only showed a trend but without statistical significance. Furthermore, ITGB3 high expression was correlated with worse progression-free survival (PFS) and overall survival (OS), while EGFL7 and KLF2 high expressions only associated with pejorative PFS but not OS. Conclusion: EGFL7, ITGB3, and KLF2 may serve as potential prognostic indicators in MM patients.

2 May 2024 in Heliyon
Verified
Journal Article
Open access
CRChunxiao Ren
Chunxiao Ren
YWYuqun Wang
Yuqun Wang
XYXin Yang
Xin Yang
YTYinglan Tuo
Yinglan Tuo
YLYaqiong Li
Yaqiong Li
JGJichang Gong
Jichang Gong
Immune checkpoint inhibitors have become one of the effective means of solid tumor treatment, among which anti-programmed death-1 (PD-1) antibodies are more maturely applied and can effectively inhibit tumor immune escape, thus enhancing the anti-tumor effect, but it can also lead to a series of immune-related adverse events (irAEs) in the process of clinical use. Here, we report a Patient with pancreatic solid pseudopapilloma treated with Sintilimab for the fifteenth cycles who developed chills, fever, and lymph node enlargement. Considering that the patient did not have infection, without history of autoimmune disease, we diagnosed the patient with Sintilimab-induced histiocytic necrotizing lymphadenitis (Kikuchi disease). The symptoms are alleviated after rapid use of glucocorticoids. Histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis) with anti-programmed death-1 (PD-1) antibody is a rare immune-related adverse events (irAEs).


10 November 2025 in Cancer Medicine
Verified
Journal Article
Open access
XCXia Cao
Xia Cao
DZDuanzong Zhang
Duanzong Zhang
JGJichang Gong
Jichang Gong
XYXin Yang
Xin Yang
JHJiqiong He
Jiqiong He
HPHongjiang Pu
Hongjiang Pu
Background: Burkitt lymphoma (BL) in middle‐aged and elderly populations presents unique prognostic challenges due to distinct biological behaviors and therapeutic vulnerabilities. Current prognostic tools inadequately address age‐specific survival determinants in this understudied cohort. Methods: This study used the Surveillance, Epidemiology, and End Results (SEER) data from patients diagnosed with BL between 2000 and 2020, aged 45 years and older. Through univariate and multivariate Cox regression analyses, we identified independent prognostic factors affecting overall survival (OS) and cancer‐specific survival (CSS). Finally, nomograms were constructed, and the models were evaluated across three dimensions. Results: Multivariate analysis results indicated that factors such as age, race, Ann Arbor stage, and chemotherapy were independently associated with OS, while age, Ann Arbor stage, radiotherapy, chemotherapy, and number of tumor masses were independently associated with CSS. The nomogram model effectively predicted the 1‐, 3‐, and 5‐year probabilities of OS and CSS. The results from receiver operating characteristic curves, calibration curves, and decision curve analysis in the training and validation groups confirmed that the risk prediction nomogram could accurately predict the survival of BL patients. Conclusion: The nomogram model constructed in this study provides a personalized survival prediction tool for BL patients, effectively distinguishing the survival probabilities of different risk groups. This research offers new insights for risk stratification and treatment management of middle‐aged and elderly BL patients.